GC
MTNB icon

Guggenheim Capital’s Matinas BioPharma MTNB Stock Holding History

Guggenheim Capital’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-427
Closed -$16K – 2521
2018
Q1 		$16K Buy
427
+12
+3% +$634 ﹤0.01% 2754
2017
Q4 		$23K Buy
+415
New +$26.7K ﹤0.01% 2666

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return

Guggenheim Capital's MTNB Position: Q2 2018 in Review

Guggenheim Capital sold out of Matinas BioPharma (MTNB) in Q2 2018, closing a stake of 427 shares — an estimated $16K sold.

Guggenheim Capital first reported a position in MTNB in Q4 2017 and held it in 2 quarters. The position peaked at $23K in Q4 2017. 39 funds tracked by Wall St. Rank hold MTNB as of Q2 2018.

  • Guggenheim Capital reported no remaining Matinas BioPharma position as of Q2 2018 after selling out during the quarter.
  • Guggenheim Capital sold 427 Matinas BioPharma shares in Q2 2018, an estimated $16K.
  • Guggenheim Capital first reported a position in Matinas BioPharma in Q4 2017 and held it in 2 quarters.
  • Guggenheim Capital's Matinas BioPharma position peaked at $23K in Q4 2017.
  • 39 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2018.

Based on Guggenheim Capital's 13F filing for Q2 2018, filed 14 Aug 2018.